Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Cosette Pharmaceuticals, Inc.
Cosette Pharmaceuticals Acquires Ambien® and Ambien CR® (Zolpidem Tartrate) Tabs from Sanofi US in the US Market
July 10, 2024
From
Cosette Pharmaceuticals, Inc.
Via
Business Wire
Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Version of RECTIV® (nitroglycerin) ointment, 0.4%, with 180 days Competitive Generic Therapy (CGT) exclusivity
February 22, 2024
From
Cosette Pharmaceuticals, Inc.
Via
Business Wire
Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.
January 03, 2024
From
Cosette Pharmaceuticals, Inc.
Via
Business Wire
Tickers
PTN
Cosette Pharmaceuticals Launches Metronidazole Vaginal Gel 0.75%, AB-rated to MetroGel-Vaginal® 0.75%
July 27, 2023
From
Cosette Pharmaceuticals, Inc.
Via
Business Wire
Cosette Pharmaceuticals Launches Dapsone 5% Gel, AB-Rated to Aczone® 5%
July 13, 2023
From
Cosette Pharmaceuticals, Inc.
Via
Business Wire
EY Announces Apurva Saraf, President and CEO of Cosette Pharmaceuticals as an Entrepreneur Of The Year® 2023 New Jersey Award Winner
June 14, 2023
From
Cosette Pharmaceuticals, Inc.
Via
Business Wire
Cosette Pharmaceuticals Launches Betaine Anhydrous Powder, AB-rated to Cystadane® (betaine anhydrous for oral solution)
March 02, 2023
From
Cosette Pharmaceuticals, Inc.
Via
Business Wire
Cosette Pharmaceuticals Announces the launch of Griseofulvin Oral Suspension, 125 mg/5 mL.
December 06, 2022
From
Cosette Pharmaceuticals, Inc.
Via
Business Wire
Cosette Pharmaceuticals Appoints Kevin Hickey, Vice President, Brand Sales and Marketing to Accelerate Transformation
November 17, 2022
From
Cosette Pharmaceuticals, Inc.
Via
Business Wire
Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Versions of TAZORAC® (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity
September 20, 2022
From
Cosette Pharmaceuticals, Inc.
Via
Business Wire
Cosette Pharmaceuticals Appoints Rick Casten as CFO Amid Transformational Growth
July 06, 2022
From
Cosette Pharmaceuticals, Inc.
Via
Business Wire
Cosette Pharmaceuticals Receives U.S. Patent (US 11,291,628) For Welchol® Chewable Bar, A Novel Oral Drug Delivery System to Deliver Colesevelam Hcl
June 07, 2022
From
Cosette Pharmaceuticals, Inc.
Via
Business Wire
Cosette Pharmaceuticals and Alembic Pharmaceuticals Limited Announce the Approval and Launch of a National Brand Equivalent (NBE) of Abreva® (Docosanol Cream 10%) Including the First Approval in the Pump Format
May 24, 2022
From
Cosette Pharmaceuticals, Inc.
Via
Business Wire
Cosette Pharmaceuticals Launches First Injectable Product - Prochlorperazine Edisylate Injection in the U.S.
February 22, 2022
From
Cosette Pharmaceuticals, Inc.
Via
Business Wire
Cosette Pharmaceuticals Acquires Rights to Eight Branded Products from Daiichi Sankyo
January 18, 2022
From
Cosette Pharmaceuticals, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.